Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Non-Small-Cell Lung 20Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Lung Neoplasms 14Mouth Neoplasms 10Laryngeal Neoplasms 10Carcinoma 10Urinary Bladder Neoplasms 8Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 6Mesothelioma, Malignant 6Medulloblastoma 6Gallbladder Neoplasms 6Neuroblastoma 5Ganglioneuroblastoma 5Fallopian Tube Neoplasms 5Lymphoid Interstitial Pneumonia 4Vulvar Neoplasms 3Urethral Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Carcinoma, Transitional Cell 3Brenner Tumor 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic NUT Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡